Clinical Trial

Accelerated vs. Standard Continuous Renal Replacement Therapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator

Study acronym: REDUCE-ECMO
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study was designed to compare the safety and efficacy of early continuous renal replacement therapy with standard continuous renal replacement therapy in the presence of acute kidney injury (stage 2 or greater acute kidney injury according to the KDIGO \[The Kidney Disease: Improving Global Outcomes\] classification) in patients with advanced cardiogenic shock on extracorporeal membrane oxygenation.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-11-17.
Status change: Not Yet Recruiting → Recruiting 2025-12-31
Trial Details
NCT Number NCT06696235
Lead Sponsor Samsung Medical Center
Conditions Cardiogenic Shock, Acute Kidney Injury
Enrollment 408 participants
Start Date 2024-12-31
Primary Completion 2028-12-31 (estimated)
Study Completion 2029-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-05